Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Devalingam Mahalingam

Showing results (41-50 of 103) with videos related to

Pageof 11
Sort By:
Cancer|July 27, 2022
A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01Vaibhav Sahai, Kent A Griffith, Muhammad S Beg, et al.
Investigational New Drugs|August 6, 2022
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumorsXiaofei Zhou, Ulka Vaishampayan, Devalingam Mahalingam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2019
Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor ActivityDevalingam Mahalingam, Judy S Wang, Erika P Hamilton, et al.
Current Drug Targets|July 23, 2011
Targeting TRAIL towards the clinicDevalingam Mahalingam, Corina N A M Oldenhuis, Eva Szegezdi, et al.
Cancers|July 15, 2026
KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase TrialsDilsa Mizrak Kaya, Yangruijue Ma, Tarik Demir, et al.
The Oncologist|May 30, 2019
Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-UpAri Joseph Rosenberg, Alfred Rademaker, Howard S Hochster, et al.
Cancer Chemotherapy and Pharmacology|May 13, 2014
Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanomaDevalingam Mahalingam, Laeeq Malik, Muralidhar Beeram, et al.
Acta Oncologica (Stockholm, Sweden)|November 16, 2017
Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx<sup>®</sup>): a placebo-controlled randomised phase II study (PLIANT)Bengt Glimelius, Nebojsa Manojlovic, Per Pfeiffer, et al.
Cancer Medicine|April 1, 2025
Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma (ACC) of all Anatomic Sites of Origin and Other Malignant Salivary Gland TumorsYoung Kwang Chae, Richard Duan, Liam Il-Young Chung, et al.
Drugs in R&D|December 23, 2015
Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid TumorsGerald S Falchook, Xiaofei Zhou, Karthik Venkatakrishnan, et al.
Pageof 11

Showing results (41-50 of 103) with videos related to

Sort By:
Pageof 11
Cancer|July 27, 2022
A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01Vaibhav Sahai, Kent A Griffith, Muhammad S Beg, et al.
Investigational New Drugs|August 6, 2022
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumorsXiaofei Zhou, Ulka Vaishampayan, Devalingam Mahalingam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2019
Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor ActivityDevalingam Mahalingam, Judy S Wang, Erika P Hamilton, et al.
Current Drug Targets|July 23, 2011
Targeting TRAIL towards the clinicDevalingam Mahalingam, Corina N A M Oldenhuis, Eva Szegezdi, et al.
Cancers|July 15, 2026
KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase TrialsDilsa Mizrak Kaya, Yangruijue Ma, Tarik Demir, et al.
The Oncologist|May 30, 2019
Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-UpAri Joseph Rosenberg, Alfred Rademaker, Howard S Hochster, et al.
Cancer Chemotherapy and Pharmacology|May 13, 2014
Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanomaDevalingam Mahalingam, Laeeq Malik, Muralidhar Beeram, et al.
Acta Oncologica (Stockholm, Sweden)|November 16, 2017
Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx<sup>®</sup>): a placebo-controlled randomised phase II study (PLIANT)Bengt Glimelius, Nebojsa Manojlovic, Per Pfeiffer, et al.
Cancer Medicine|April 1, 2025
Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma (ACC) of all Anatomic Sites of Origin and Other Malignant Salivary Gland TumorsYoung Kwang Chae, Richard Duan, Liam Il-Young Chung, et al.
Drugs in R&D|December 23, 2015
Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid TumorsGerald S Falchook, Xiaofei Zhou, Karthik Venkatakrishnan, et al.
Pageof 11